You are here

Share:

Search Technologies

Showing 1-20 of 315 results found

Human Antibodies and Fusion Proteins as HIV-1 Therapeutic

NCI Cancer and Inflammation Program researchers developed multiple novel human anti-HIV-1 domain antibodies and their fusion proteins with two-domain or single-domain human soluble CD4 that can potentially be used alone or synergistically with other anti-HIV-1 antibodies and antiretroviral drugs as therapeutics and/or preventatives for infection by different HIV-1 strains. These are available for co-development and licensing.

Engineered Biological Pacemakers

The National Institute on Aging's Cellular Biophysics Section is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize biological pacemakers.

Alteration of p53 Isoform expression to Treat Age-Related Disorders and Cancer

Inhibition of delta133p53 may be a novel approach for cell senescence-mediated anti-proliferative therapy, including anti-cancer treatments. In addition, enhanced expression of delta 133p53 can extend the replicative lifespan of normal human cells. Therefore, this technology may provide a new method in the field of regenerative medicine for aging-related degenerative disease as well as cancer therapeutics. The National Cancer Institute seeks parties to co-develop or license a new method for inhibiting aging-related degenerative disease and cancer.

Biological Semiconductors

The National Cancer Institute's Cancer Diagnostic Program and the Food and Drug Administration's Center for Devices and Radiological Health is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize biological semiconductors as diagnostic sensors.

BODIPY-FL Nilotinib (Tasigna) for Use in Cancer Research

The National Cancer Institute''s Laboratory of Cell Biology is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize bodipy conjugated tyrosine kinase inhibitors that are currently used in the clinic for the treatment of CML or gastric cancers.

Screening of Menkes Disease in Newborns that are likely to Benefit from Copper Treatment

The Eunice Kennedy Shriver National Institute of Child Health and Human Development's (NICHD) Molecular Medicine Program is seeking statements of capability or interest from parties interested in collaborative research to further develop, or evaluate on a large-scale, population-based newborn screening for Menkes disease (also known as kinky hair disease).

Assay for Arf GTP-binding Proteins

The National Cancer Institute's Laboratory of Cellular and Molecular Biology is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize an antibody-based proteomics assay.

Synergistic Combination Agent for Cancer Therapy

The Nanotechnology Characterization Laboratory of the Frederick National Laboratory for Biomedical Research seeks parties interested in collaborative research to co-develop a ceramide and vinca alkaloid combination therapy for treatment of cancer.

Ketamine Metabolites for the Treatment of Depression and Pain

The National Institute on Aging, Laboratory of Clinical Investigation, is seeking parties interested in collaborative research to co-develop ketamine metabolites for the treatment of different forms of depression and for alleviating pain.

MUC-1 Tumor Antigen Agonist Epitopes for Enhancing T-cell Responses to Human Tumors

Scientists at NIH have identified 7 new agonist epitopes of the MUC-1 tumor associated antigen. Compared to their native epitope counterparts, peptides reflecting these agonist epitopes have been shown to enhance the generation of human tumor cells, which in turn have a greater ability to kill human tumor cells endogenously expressing the native MUC-1 epitope.

Angiogenesis-Based Cancer Therapeutic

The National Cancer Institute's Urologic Oncology Branch seeks interested parties to co-develop antagonists to VEGF-A and hepatocyte growth factor (HGF) that block signal transduction and associated cellular responses.

Pages